Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Current Liabilities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Total Current Liabilities for 4 consecutive years, with $24.2 million as the latest value for Q1 2025.

  • On a quarterly basis, Total Current Liabilities fell 11.78% to $24.2 million in Q1 2025 year-over-year; TTM through Mar 2025 was $24.2 million, a 11.78% decrease, with the full-year FY2024 number at $58.0 million, up 47.26% from a year prior.
  • Total Current Liabilities was $24.2 million for Q1 2025 at Centessa Pharmaceuticals, down from $58.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $58.0 million in Q4 2024 to a low of $24.2 million in Q1 2025.
  • A 4-year average of $35.8 million and a median of $35.9 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 47.26% in 2024, then dropped 11.78% in 2025.
  • Centessa Pharmaceuticals' Total Current Liabilities stood at $38.3 million in 2022, then rose by 2.73% to $39.4 million in 2023, then surged by 47.26% to $58.0 million in 2024, then plummeted by 58.27% to $24.2 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Total Current Liabilities are $24.2 million (Q1 2025), $58.0 million (Q4 2024), and $27.4 million (Q1 2024).